PPC
MCID: PRM126
MIFTS: 59

Primary Peritoneal Carcinoma (PPC)

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Primary Peritoneal Carcinoma

MalaCards integrated aliases for Primary Peritoneal Carcinoma:

Name: Primary Peritoneal Carcinoma 59 37 73
Serous Surface Papillary Carcinoma 59 73
Extra-Ovarian Primary Peritoneal Carcinoma 59
Primary Peritoneal Serous Adenocarcinoma 73
Primary Peritoneal Serous Carcinoma 59
Eoppc 59
Ppc 59

Characteristics:

Orphanet epidemiological data:

59
primary peritoneal carcinoma
Age of onset: Adult; Age of death: normal life expectancy;

Classifications:



External Ids:

Orphanet 59 ORPHA168829
ICD10 via Orphanet 34 C48.2
KEGG 37 H01665

Summaries for Primary Peritoneal Carcinoma

MalaCards based summary : Primary Peritoneal Carcinoma, also known as serous surface papillary carcinoma, is related to papillary serous adenocarcinoma and inflammatory breast carcinoma. An important gene associated with Primary Peritoneal Carcinoma is BRCA1 (BRCA1, DNA Repair Associated), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Dexamethasone and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and bone, and related phenotypes are nausea and vomiting and constipation

Wikipedia : 76 Primary peritoneal cancer or carcinoma is also known as serous surface papillary carcinoma, primary... more...

Related Diseases for Primary Peritoneal Carcinoma

Diseases in the Peritoneal Benign Neoplasm family:

Primary Peritoneal Carcinoma

Diseases related to Primary Peritoneal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 204)
# Related Disease Score Top Affiliating Genes
1 papillary serous adenocarcinoma 33.0 BRCA1 PGR TP53
2 inflammatory breast carcinoma 30.1 EGFR ERBB2 PGR
3 ovarian cancer 1 29.8 BRCA1 BRCA2 ERBB2 TP53 VEGFA
4 endometriosis 29.8 CXCL8 PGR VEGFA
5 in situ carcinoma 29.7 BRCA1 EGFR ERBB2 PGR TP53
6 adenocarcinoma 29.7 EGFR ERBB2 RET TP53 VEGFA
7 papillary carcinoma 29.6 ERBB2 PGR RET
8 fallopian tube carcinoma 29.2 BRCA1 BRCA2 ERBB2 PGR TP53 VEGFA
9 ovarian cancer 29.0 BRCA1 BRCA2 EGFR ERBB2 ERCC1 MIR195
10 breast cancer 28.5 BRCA1 BRCA2 CXCL8 EGFR ERBB2 MIR195
11 ovary papillary carcinoma 11.5
12 breast-ovarian cancer, familial 1 10.3 BRCA1 BRCA2
13 hereditary site-specific ovarian cancer syndrome 10.3 BRCA1 BRCA2
14 nickel allergic contact dermatitis 10.3 IFNG IL10
15 sporotrichosis 10.3 IFNG IL10
16 tungiasis 10.3 CXCL8 IL10
17 vulvovaginitis 10.3 CXCL8 IL10
18 scabies 10.3 CXCL8 IL10
19 acute transverse myelitis 10.3 CXCL8 IL10
20 pouchitis 10.3 CXCL8 IL10
21 breast intraductal proliferative lesion 10.3 EGFR ERBB2
22 progesterone-receptor positive breast cancer 10.2 ERBB2 PGR
23 breast reconstruction 10.2 BRCA1 BRCA2
24 oncocytic breast carcinoma 10.2 EGFR PGR
25 tuberculous salpingitis 10.2 BRCA1 BRCA2 ERBB2
26 fallopian tube adenocarcinoma 10.2 BRCA1 BRCA2 ERBB2
27 scirrhous adenocarcinoma 10.2 ERBB2 PGR
28 breast apocrine carcinoma 10.2 ERBB2 PGR
29 pleomorphic adenoma carcinoma 10.2 ERBB2 TP53
30 non-proliferative fibrocystic change of the breast 10.2 ERBB2 TP53
31 asymptomatic neurosyphilis 10.2 CXCL10 CXCL8 IFNG
32 vesicoureteral reflux 1 10.2
33 viral meningitis 10.2 CXCL10 CXCL8 IFNG
34 lung papillary adenocarcinoma 10.2 ERCC1 TP53
35 glassy cell carcinoma of the cervix 10.2 ERBB2 PGR
36 actinic cheilitis 10.2 ERCC1 TP53
37 fanconi anemia, complementation group q 10.2 BRCA1 BRCA2 ERCC1
38 invasive aspergillosis 10.2 CXCL10 CXCL8 IFNG
39 cephalosporin allergy 10.2 IFNG IL10
40 mycobacterium tuberculosis 1 10.2 CXCL10 IFNG IL10
41 demyelinating disease 10.2 CXCL10 IFNG IL10
42 severe acute respiratory syndrome 10.2 CXCL10 CXCL8 IFNG
43 nosophobia 10.2 BRCA1 BRCA2 PGR
44 cancerophobia 10.2 BRCA1 BRCA2 PGR
45 mucinous lung adenocarcinoma 10.2 CXCL10 EGFR ERBB2
46 bacterial infectious disease 10.2 CXCL8 IFNG IL10
47 fungal meningitis 10.2 CXCL10 IFNG IL10
48 breast malignant phyllodes tumor 10.2 PGR TP53
49 peanut allergy 10.2 CXCL10 IFNG IL10
50 olfactory groove meningioma 10.2 PGR TP53

Graphical network of the top 20 diseases related to Primary Peritoneal Carcinoma:



Diseases related to Primary Peritoneal Carcinoma

Symptoms & Phenotypes for Primary Peritoneal Carcinoma

Human phenotypes related to Primary Peritoneal Carcinoma:

59 32 (show all 6)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 59 32 hallmark (90%) Very frequent (99-80%) HP:0002017
2 constipation 59 32 hallmark (90%) Very frequent (99-80%) HP:0002019
3 abdominal pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0002027
4 neoplasm 59 32 hallmark (90%) Very frequent (99-80%) HP:0002664
5 abdominal distention 59 32 hallmark (90%) Very frequent (99-80%) HP:0003270
6 peritonitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002586

GenomeRNAi Phenotypes related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

26 (show all 36)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.29 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.29 ERCC1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.29 IL10
4 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.29 EGFR
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.29 EGFR
6 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.29 IL10
7 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.29 IL10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.29 RET
9 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.29 IL10 RET
10 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.29 IL10
11 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.29 ERBB2 ERCC1 IL10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.29 ERBB2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.29 RET
14 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.29 ERBB2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.29 ERCC1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.29 RET
17 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.29 EGFR
18 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.29 IL10
19 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.29 ERBB2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.29 EGFR
21 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.29 IL10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.29 EGFR IL10
23 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.29 IL10 RET
24 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.29 ERBB2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.29 EGFR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.29 IL10 RET
27 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.29 ERBB2 ERCC1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.29 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.29 RET
30 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.29 IL10
31 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.29 IL10
32 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.29 EGFR ERBB2 ERCC1 IL10 RET
33 Decreased viability with paclitaxel GR00179-A-1 9.46 EGFR ERBB2 IL10
34 Decreased viability with paclitaxel GR00179-A-3 9.46 EGFR
35 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 BRCA1 BRCA2 CXCL8 ERCC1 IL10 TP53
36 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 BRCA1 BRCA2 CXCL8 ERCC1 IL10 TP53

MGI Mouse Phenotypes related to Primary Peritoneal Carcinoma:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.36 BRCA1 BRCA2 CXCL10 EGFR ERBB2 ERCC1
2 embryo MP:0005380 10.31 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG
3 homeostasis/metabolism MP:0005376 10.31 BRCA1 BRCA2 CXCL10 EGFR ERBB2 ERCC1
4 behavior/neurological MP:0005386 10.3 BRCA1 BRCA2 ERBB2 ERCC1 IFNG IL10
5 endocrine/exocrine gland MP:0005379 10.3 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG
6 cardiovascular system MP:0005385 10.29 BRCA1 CXCL10 EGFR ERBB2 IFNG IL10
7 hematopoietic system MP:0005397 10.29 BRCA1 BRCA2 CXCL10 EGFR ERCC1 IFNG
8 immune system MP:0005387 10.26 BRCA1 BRCA2 CXCL10 EGFR ERCC1 IFNG
9 mortality/aging MP:0010768 10.26 BRCA1 BRCA2 CXCL10 EGFR ERBB2 ERCC1
10 digestive/alimentary MP:0005381 10.23 BRCA1 BRCA2 EGFR ERBB2 IFNG IL10
11 integument MP:0010771 10.21 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG
12 neoplasm MP:0002006 10.17 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG
13 muscle MP:0005369 10.16 BRCA1 EGFR ERBB2 ERCC1 IFNG IL10
14 limbs/digits/tail MP:0005371 10.15 BRCA1 BRCA2 EGFR ERBB2 IL10 PGR
15 nervous system MP:0003631 10.1 BRCA1 BRCA2 CXCL10 EGFR ERBB2 IFNG
16 normal MP:0002873 10.02 BRCA1 BRCA2 EGFR ERBB2 IFNG IL10
17 no phenotypic analysis MP:0003012 9.91 EGFR IFNG IL10 PGR RET TP53
18 reproductive system MP:0005389 9.9 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG
19 renal/urinary system MP:0005367 9.8 BRCA1 EGFR ERCC1 IFNG RET TP53
20 respiratory system MP:0005388 9.56 BRCA1 EGFR ERBB2 IFNG IL10 RET
21 skeleton MP:0005390 9.32 BRCA1 BRCA2 EGFR ERBB2 ERCC1 IFNG

Drugs & Therapeutics for Primary Peritoneal Carcinoma

Drugs for Primary Peritoneal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 334)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
3 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
11 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
16
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
17
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
18
Cisplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
19
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
20
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 123948-87-8, 119413-54-6 60700
21
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
22
Tamoxifen Approved Phase 3,Phase 2 10540-29-1 2733526
23
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 216974-75-3
24
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
25
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
26
Olaparib Approved Phase 2, Phase 3,Phase 3,Phase 1 763113-22-0 23725625
27
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
28
Niraparib Approved, Investigational Phase 3,Phase 2,Phase 1 1038915-60-4 24958200
29
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
30
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
31
Rucaparib Approved, Investigational Phase 3,Phase 2,Phase 1 283173-50-2 9931954
32
Atezolizumab Approved, Investigational Phase 3,Phase 2,Phase 1 1380723-44-3
33
Adenosine Approved, Investigational Phase 3,Phase 2 58-61-7 60961
34 Talazoparib Approved, Investigational Phase 3,Phase 1,Phase 2,Early Phase 1 1207456-01-6
35
Mechlorethamine Approved, Investigational Phase 3,Phase 1 51-75-2 4033
36
Ifosfamide Approved Phase 3 3778-73-2 3690
37
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
38
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
40
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Early Phase 1 56-86-0 33032
41
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
42
Trebananib Investigational Phase 3,Phase 2,Phase 1 894356-79-7
43
Saracatinib Investigational Phase 2, Phase 3 379231-04-6
44
Veliparib Investigational Phase 3,Phase 2,Phase 1 912444-00-9 11960529
45
Cediranib Investigational Phase 2, Phase 3,Phase 3,Phase 1 288383-20-0 9933475
46
Maleic acid Experimental Phase 2, Phase 3,Phase 3,Phase 1 110-16-7 444266
47 Immunoglobulins Phase 3,Phase 2,Phase 1,Not Applicable
48 Antibodies Phase 3,Phase 2,Phase 1,Not Applicable
49 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 572)
# Name Status NCT ID Phase Drugs
1 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
2 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy Unknown status NCT00004115 Phase 3
3 ICON8: Weekly Chemotherapy in Ovarian Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
4 Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
5 Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
6 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Completed NCT00011986 Phase 3 Paclitaxel;Carboplatin;Gemcitabine Hydrochloride;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
7 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
8 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
9 Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00866697 Phase 3 Pazopanib;Placebo
10 A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. Completed NCT00191607 Phase 3 Gemcitabine;liposomal doxorubicin
11 Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00098878 Phase 3 carboplatin
12 TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer Completed NCT01204749 Phase 3 AMG 386;AMG 386 Placebo;Paclitaxel;Paclitaxel
13 A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin
14 Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer Completed NCT02311907 Phase 3 Carboplatin;Glutathione;Paclitaxel
15 Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00002895 Phase 3 chemotherapy
16 Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer Completed NCT01196741 Phase 2, Phase 3 Paclitaxel;Saracatinib;Matched placebo
17 Study of Paclitaxel in Patients With Ovarian Cancer Completed NCT00989131 Phase 3 Paclical®;Taxol®
18 S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Completed NCT00003120 Phase 3 paclitaxel
19 Comparison of Combination Chemotherapy Regimens in Treating Newly Diagnosed Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT00028743 Phase 3 carboplatin;cisplatin;paclitaxel;topotecan hydrochloride
20 Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer Completed NCT00262990 Phase 3 EPO906 (Patupilone);doxorubicin
21 AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer Completed NCT00976911 Phase 3 bevacizumab [Avastin];liposomal doxorubicin;paclitaxel;topotecan
22 Accelerating Gastrointestinal Recovery Completed NCT01704651 Phase 3 Alvimopan;Placebo
23 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
24 OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
25 An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy Completed NCT00191646 Phase 3 Gemcitabine;Paclitaxel;Carboplatin
26 S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer Completed NCT00043082 Phase 3 carboplatin;pegylated liposomal doxorubicin hydrochloride
27 TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer Completed NCT00102973 Phase 3 TLK286 in Combination with Carboplatin;Doxorubicin HCl Liposome Injection
28 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
29 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
30 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma Recruiting NCT02328716 Phase 3 Hipec with Cisplatin
31 A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT03635489 Phase 3 Paclitaxel;Bevacizumab;Carboplatin;Placebo
32 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Recruiting NCT02855944 Phase 3 Chemotherapy;Rucaparib
33 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
34 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
35 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT03038100 Phase 3 Paclitaxel;Carboplatin;Atezolizumab;Bevacizumab;Atezolizumab Placebo
36 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
37 Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient Recruiting NCT03705156 Phase 3 ZL-2306(nirapairb);Placebos
38 Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer Recruiting NCT03632798 Phase 3 Chemotherapy
39 Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) Recruiting NCT03642132 Phase 3 Chemotherapy + avelumab followed by avelumab + talazoparib;Chemotherapy followed by talazoparib maintenance;Chemotherapy + bevacizumab followed by bevacizumab
40 A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer Recruiting NCT03709316 Phase 3 ZL-2306 (Nirapairb);Placebo Comparator
41 Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) Recruiting NCT02859038 Phase 3
42 Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? Recruiting NCT01611766 Phase 3 Salvage Chemotherapy
43 Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer Recruiting NCT03353831 Phase 3 Bevacizumab;Atezolizumab;Chemotherapy;Placebos
44 Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Recruiting NCT03534453 Phase 3 Olaparib 300mg tablets
45 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/ENGOT-ov43/KEYLYNK-001) Recruiting NCT03740165 Phase 3 Placebo for pembrolizumab;Carboplatin;Paclitaxel;Olaparib;Placebo for olaparib
46 Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Recruiting NCT02032823 Phase 3 Olaparib;Placebo
47 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
48 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
49 Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02470585 Phase 3 Veliparib;Paclitaxel;Veliparib;Carboplatin
50 Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial Active, not recruiting NCT01506856 Phase 2, Phase 3 Paclitaxel(intravenous) + Carboplatin(intravenous);Paclitaxel(intravenous) + Carboplatin(intraperitoneal)

Search NIH Clinical Center for Primary Peritoneal Carcinoma

Genetic Tests for Primary Peritoneal Carcinoma

Anatomical Context for Primary Peritoneal Carcinoma

MalaCards organs/tissues related to Primary Peritoneal Carcinoma:

41
Ovary, Endothelial, Bone, Brain, Lung, Colon, Pancreas

Publications for Primary Peritoneal Carcinoma

Articles related to Primary Peritoneal Carcinoma:

(show top 50) (show all 136)
# Title Authors Year
1
Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients. ( 29782365 )
2018
2
Multicenter Clinicopathological Study of High-Grade Serous Carcinoma Presenting as Primary Peritoneal Carcinoma. ( 29324533 )
2018
3
Cauda equina syndrome secondary to leptomeningeal metastases from recurrent primary peritoneal carcinoma. ( 29515655 )
2018
4
Diagnostic and prognostic value of HE4 in female patients with primary peritoneal carcinoma. ( 30238835 )
2018
5
A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. ( 28698009 )
2017
6
Brain metastasis from primary peritoneal carcinoma: Case report and literature review. ( 28279555 )
2017
7
Clinical characteristics of primary peritoneal carcinoma patients: a single-institution experience involving 8 patients. ( 28008196 )
2016
8
Primary peritoneal carcinoma metastasizing to breast: a single case report and literature review from clinic to biology. ( 27807506 )
2016
9
Primary peritoneal carcinoma presenting as a Sister Mary Joseph's nodule: A case report and review of the literature. ( 27354995 )
2016
10
Outcomes Following Interval Debulking Surgery in Primary Peritoneal Carcinoma. ( 26722051 )
2016
11
Primary Peritoneal Carcinoma in a BRCA1/2-negative, PALB2-positive patient. ( 27547810 )
2016
12
An unusual cancer involving the rectum: two cases of localized primary peritoneal carcinoma mimicking rectal carcinoma. ( 25913798 )
2015
13
Low-grade serous primary peritoneal carcinoma incidentally found in a hernia sac. ( 25953339 )
2015
14
Primary peritoneal serous papillary carcinoma presenting as a large mesenteric mass mistaken for ovarian cancer: a case of primary peritoneal carcinoma. ( 26023675 )
2015
15
A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma. ( 26026738 )
2015
16
Primary Peritoneal Carcinoma Initially Presenting as Atypical Cervical Lymphadenopathy. ( 26120309 )
2015
17
Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236). ( 26335594 )
2015
18
Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). ( 26089092 )
2015
19
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. ( 24709487 )
2014
20
Primary peritoneal carcinoma: regional cancer institute experience. ( 25419074 )
2014
21
Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma. ( 24798935 )
2014
22
Effect of Tubal Sterilization Technique on Risk of Serous Ovarian and Primary Peritoneal Carcinoma. ( 25316178 )
2014
23
Cytoreductive surgery under aminolevulinic Acid-mediated photodynamic diagnosis plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from ovarian cancer and primary peritoneal carcinoma: results of a phase I trial. ( 25056850 )
2014
24
Treatment and prognostic factors in primary peritoneal carcinoma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). ( 24903764 )
2014
25
A case of primary peritoneal carcinoma: evidence for a precursor in the fallopian tube. ( 24403495 )
2014
26
Solitary primary peritoneal carcinoma arising from the omentum. ( 25017281 )
2014
27
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. ( 25016924 )
2014
28
Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182. ( 23791702 )
2013
29
Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube, or primary peritoneal carcinoma. ( 23748176 )
2013
30
A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study. ( 24361733 )
2013
31
The effect of age on first-line chemotherapy for epithelial ovarian cancer and primary peritoneal carcinoma. ( 23146339 )
2013
32
Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience. ( 23435437 )
2013
33
Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. ( 22960352 )
2013
34
A case of extraovarian primary peritoneal carcinoma in an oophorectomized-hysterectomized patient: a diagnostic dilemma. ( 23578412 )
2013
35
Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma. ( 24073344 )
2013
36
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. ( 22037316 )
2012
37
Paclitaxel plus Carboplatin Chemotherapy for Primary Peritoneal Carcinoma: A Study of 22 Cases and Comparison with Stage III-IV Ovarian Serous Carcinoma. ( 22666209 )
2012
38
Comparison between peritoneal tuberculosis and primary peritoneal carcinoma: a 16-year, single-center experience. ( 22964319 )
2012
39
Cutaneous lymphangitis carcinomatosis metastasis of extra-ovarian primary peritoneal carcinoma. ( 22949038 )
2012
40
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. ( 22047770 )
2012
41
Prognosis of primary peritoneal carcinoma: effect of cytoreductive surgery combined with neoadjuvant chemotherapy after laparoscopic diagnosis and evaluation: a multi-center trial. ( 22439406 )
2012
42
A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( 22155262 )
2012
43
A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( 22366594 )
2012
44
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( 22710075 )
2012
45
Isolated metastatic primary peritoneal carcinoma to the breast: a rare site of disease recurrence. ( 22391350 )
2012
46
Extraovarian primary peritoneal carcinoma: staging with 18F-FDG PET/CT. ( 21394599 )
2012
47
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. ( 22772063 )
2012
48
A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( 22943879 )
2012
49
A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. ( 22664059 )
2012
50
A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. ( 22446624 )
2012

Variations for Primary Peritoneal Carcinoma

Cosmic variations for Primary Peritoneal Carcinoma:

9 (show all 17)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM44684 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.965C>T p.P322L 17:7673563-7673563 7
2 COSM43850 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.659A>C p.Y220S 17:7674872-7674872 7
3 COSM44338 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.845G>A p.R282Q 17:7673775-7673775 7
4 COSM10758 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.659A>G p.Y220C 17:7674872-7674872 7
5 COSM44764 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.673G>T p.V225F 17:7674290-7674290 7
6 COSM43989 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.596G>A p.G199E 17:7674935-7674935 7
7 COSM44769 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.755T>C p.L252P 17:7674208-7674208 7
8 COSM43737 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.830G>A p.C277Y 17:7673790-7673790 7
9 COSM44683 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.652G>A p.V218M 17:7674879-7674879 7
10 COSM10704 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.844C>T p.R282W 17:7673776-7673776 7
11 COSM11073 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.1024C>T p.R342* 17:7670685-7670685 7
12 COSM11071 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.1009C>T p.R337C 17:7670700-7670700 7
13 COSM10988 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.772G>A p.E258K 17:7674191-7674191 7
14 COSM10794 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.796G>A p.G266R 17:7673824-7673824 7
15 COSM10662 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.743G>A p.R248Q 17:7674220-7674220 7
16 COSM44603 TP53 peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.835G>A p.G279R 17:7673785-7673785 7
17 COSM520 KRAS peritoneum,NS,carcinoma,peritoneal serous surface carcinoma c.35G>T p.G12V 12:25245350-25245350 7

Expression for Primary Peritoneal Carcinoma

Search GEO for disease gene expression data for Primary Peritoneal Carcinoma.

Pathways for Primary Peritoneal Carcinoma

Pathways related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 CXCL10 CXCL8 EGFR ERBB2 FOLR3 IFNG
2
Show member pathways
13.47 BRCA1 CXCL8 EGFR ERBB2 IFNG IL10
3
Show member pathways
13.08 CXCL10 CXCL8 EGFR ERBB2 IFNG IL10
4
Show member pathways
12.76 BRCA2 EGFR ERBB2 RET TP53 VEGFA
5
Show member pathways
12.64 BRCA1 BRCA2 EGFR ERBB2 TP53 VEGFA
6
Show member pathways
12.62 BRCA1 BRCA2 EGFR ERBB2 PGR TP53
7
Show member pathways
12.48 EGFR ERBB2 IFNG IL10 TP53
8 12.45 BRCA1 BRCA2 ERCC1 TP53
9
Show member pathways
12.41 EGFR ERBB2 TP53 VEGFA
10 12.24 EGFR ERBB2 TP53 VEGFA
11 12.21 BRCA1 EGFR ERBB2 MIR195 TP53 VEGFA
12
Show member pathways
12.17 CXCL8 EGFR IFNG IL10 TP53
13 12.1 EGFR IFNG TP53 VEGFA
14 12.09 CXCL8 IL10 RET VEGFA
15 11.99 BRCA1 BRCA2 EGFR TP53 VEGFA
16
Show member pathways
11.98 BRCA1 CXCL8 EGFR IFNG IL10
17 11.95 BRCA2 CXCL8 EGFR ERBB2 IFNG RET
18
Show member pathways
11.89 EGFR ERBB2 PGR
19 11.88 CXCL8 IFNG TP53
20 11.88 CXCL8 IL10 TP53 VEGFA
21 11.83 CXCL8 IFNG IL10
22 11.82 BRCA1 BRCA2 ERCC1
23
Show member pathways
11.81 EGFR ERBB2 VEGFA
24 11.81 EGFR ERBB2 IFNG VEGFA
25 11.79 CXCL8 IFNG VEGFA
26
Show member pathways
11.75 BRCA1 BRCA2 TP53
27 11.74 CXCL8 IFNG TP53
28 11.67 CXCL10 IFNG IL10
29 11.64 BRCA1 ERBB2 TP53
30 11.63 CXCL10 CXCL8 EGFR IFNG TP53
31 11.62 BRCA1 ERBB2 ERCC1 TP53
32
Show member pathways
11.61 CXCL8 IFNG VEGFA
33 11.55 EGFR ERBB2 RET TP53
34 11.54 BRCA1 CXCL8 IFNG
35 11.5 EGFR IFNG TP53
36 11.47 CXCL10 CXCL8 IL10
37 11.46 CXCL8 IFNG IL10
38 11.45 EGFR RET VEGFA
39 11.38 BRCA1 CXCL8 TP53 VEGFA
40 11.22 CXCL8 EGFR ERBB2 TP53 VEGFA
41 10.96 CXCL10 CXCL8 EGFR ERBB2 IL10

GO Terms for Primary Peritoneal Carcinoma

Cellular components related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lateral element GO:0000800 8.62 BRCA1 BRCA2

Biological processes related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.95 CXCL10 CXCL8 IFNG IL10 VEGFA
2 positive regulation of transcription, DNA-templated GO:0045893 9.91 BRCA1 BRCA2 EGFR IL10 RET TP53
3 cell surface receptor signaling pathway GO:0007166 9.9 CXCL10 EGFR ERBB2 IFNG
4 cell proliferation GO:0008283 9.89 BRCA2 EGFR ERBB2 ERCC1 TP53
5 positive regulation of cell migration GO:0030335 9.88 CXCL10 EGFR RET VEGFA
6 negative regulation of apoptotic process GO:0043066 9.85 EGFR ERBB2 IL10 RET TP53 VEGFA
7 positive regulation of protein phosphorylation GO:0001934 9.83 EGFR ERBB2 IFNG VEGFA
8 DNA recombination GO:0006310 9.8 BRCA1 BRCA2 ERCC1
9 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.79 EGFR ERBB2 RET
10 double-strand break repair GO:0006302 9.75 BRCA1 BRCA2 ERCC1
11 positive regulation of epithelial cell proliferation GO:0050679 9.74 EGFR ERBB2 VEGFA
12 positive regulation of MAP kinase activity GO:0043406 9.73 EGFR ERBB2 VEGFA
13 nucleotide-excision repair GO:0006289 9.65 BRCA2 ERCC1 TP53
14 cytokine-mediated signaling pathway GO:0019221 9.65 CXCL10 CXCL8 IL10 TP53 VEGFA
15 induction of positive chemotaxis GO:0050930 9.62 CXCL8 VEGFA
16 response to molecule of bacterial origin GO:0002237 9.61 CXCL8 IL10
17 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.59 EGFR TP53
18 negative regulation of mitotic cell cycle GO:0045930 9.58 EGFR IL10 MIR195
19 negative regulation of ERBB signaling pathway GO:1901185 9.54 EGFR ERBB2
20 response to gamma radiation GO:0010332 9.5 BRCA2 CXCL10 TP53
21 chordate embryonic development GO:0043009 9.46 BRCA1 BRCA2
22 positive regulation of gene expression GO:0010628 9.43 BRCA1 ERBB2 IFNG RET TP53 VEGFA
23 leukocyte chemotaxis GO:0030595 9.33 CXCL10 CXCL8 IL10
24 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 BRCA1 BRCA2 TP53
25 positive regulation of transcription by RNA polymerase II GO:0045944 10.05 BRCA1 CXCL10 EGFR IL10 PGR TP53

Molecular functions related to Primary Peritoneal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.5 BRCA1 BRCA2 EGFR ERBB2 PGR TP53
2 protein phosphatase binding GO:0019903 9.43 EGFR ERBB2 TP53
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 EGFR ERBB2 RET
4 TFIID-class transcription factor complex binding GO:0001094 9.32 ERCC1 TP53
5 cytokine activity GO:0005125 9.02 CXCL10 CXCL8 IFNG IL10 VEGFA

Sources for Primary Peritoneal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....